Mr. Fan is a partner in the firm’s Beijing office. Mr. Fan advises global and Chinese corporate clients and investment funds on mergers and acquisitions, including strategic investments, private equity transactions, foreign direct investments, joint ventures, buyouts, sales, pre-IPO financings, PIPEs and going-private transactions. He also has experience advising on securities offerings and general corporate matters.

Mr. Fan worked at the firm's Beijing office from 2009 to 2010. He then worked at Shearman & Sterling LLP for five years and Davis Polk & Wardwell LLP for almost six years. Before rejoining the firm in 2021, he was counsel in the corporate practice of Davis Polk & Wardwell LLP.

Mr. Fan’s representative M&A matters include advising:

Private M&A: PAG in the buyout of cinema management business of Seazen Group; Warburg Pincus in the trade sale of Amcare Healthcare to ByteDance; A-share listed company Sirio Pharma in its acquisition of Best Formulations; RISE Education in its merger with NaaS; Danfoss China in its sale of orbital motors business; Heineken in its strategic partnership with China Resources in China; the consortium led by Tencent in its acquisition of a minority stake in Universal Music Group from Vivendi; Tencent and TME in their investments in Spotify, and in the cross-shareholding by Spotify in TME; Uber in the merger of Uber China and Didi Chuxing; TPG in its investment in Du Xiaoman Financial; Tencent in its acquisition of a majority stake of China Music Corporation and the combination of QQ Music and China Music Corporation; IDG Capital in its acquisition of International Data Group; Bain Capital, Warburg Pincus, TPG, Hillhouse, CPE, IDG Capital, Centurium Capital, and certain sovereign wealth funds in various private equity investments; Megvii, iQiyi, TME, JinkoSolar in several rounds of private financing; the buyer group in its attempted acquisition of iQiyi from Baidu; Bank of Communications in its acquisition of Banco BBM in Brazil.

Public M&A: the special committee in the acquisition transactions of US-listed companies including Hollysys, CBPO, 51job, AsiaInfo, Trunkbow, Dangdang, China Nepstar, Bona Film, Zhangmen Education, Simcere, and China TransInfo; the buyer consortium or its members in the going private transactions of US-listed companies including 111, Inc., Bright Scholar, Sogou, 58.com, Synutra, KongZhong, and China Cord Blood; iKang Healthcare and Yintech in their respective going-private transactions; DouYu and its special committee in the proposed stock-for-stock merger with Huya; China Biologic Products in its PIPE issuance of shares to Centurium Capital, CITIC Capital, Hillhouse Capital and PW Medtech; several de-SPAC transactions involving targets in TMT and healthcare sectors; Qunar in its private placement of convertible notes to Silver Lake and Hillhouse.

Mr. Fan received his LL.B. degree from Wuhan University in 2005 and LL.M. degree from Peking University in 2007, respectively. He also received an LL.M. degree from New York University in 2008, where he was a Hugo Grotius scholar.

PRC

New York

Mr. Fan is a native Mandarin speaker and is fluent in English.